Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
osphena
Synonyms :
Ospemifene, ospemifeno
Class :
Selective estrogen receptor modulators
Dosage Forms & Strengths
Tablet
60mg
60
mg
Tablet
Orally
every day with food
60
mg
Tablet
Orally
every day with food
ospemifene may diminish the therapeutic effects of raloxifene or may enhance adverse toxic effects of raloxifene
relugolix/estradiol/norethindrone
may enhance the effects of the other by pharmacodynamic synergism
the activity of either of the drugs is increased by pharmacodynamic synergism
may increase the adverse effect
bazedoxifene/conjugated estrogens
may increase the adverse effect
may increase the adverse effect
may increase the adverse effect
may increase the adverse effect
may increase the serum concentration of CYP3A4 substrates
may enhance the serum concentration
may increase the serum concentration of CYP3A4 substrates
enzalutamide may reduce the therapeutic efficacy of ospemifene
estrogens esterified/methyltestosterone
may increase the adverse effect when combined
may diminish the serum concentration
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of CYP3A4 substrates
may diminish the serum concentration
may increase the serum concentration
It may enhance the effect when combined with estradiol valerate by pharmacodynamic synergism
may diminish the therapeutic effects of tamoxifen
the effect of ospemifene is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
the level of effect of ospemifene is increased by fluorouracil, by impacting CYP2C9/10 hepatic enzyme metabolism
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
It may enhance the risk of adverse effects when combined with dopamine receptors antagonists
Frequency defined:
1-10%
Vaginal discharge
Hot flush
Muscle spasm
Genital discharge
Post-marketing reports
Angioedema
Erythematous rash
Pruritis
Neoplasm
Hypersensitivity
Rash
Generalized rash
Urticaria
Deep vein thrombosis
Pregnancy consideration:
US FDA pregnancy category: X
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: ospemifene
Pronounced: [os-pem-i-feen]
Why do we use ospemifene?
It is used to treat mild to severe dyspareunia (painful sex and vaginal dryness), which is caused by menopause